Kedrion’s global commitment to improving the living conditions of people suffering from rare diseases also runs through our partnerships with communities and health systems around the world that strive for national self-sufficiency in plasma-derived therapies.
The latest addition to our international contract manufacturing pipeline is Portugal, where a national tender for manufacturing plasma into medicines was awarded to Kedrion in late 2022.
The first shipments of Portuguese plasma coming from the blood centers in Porto and Lisbon occurred on January 31st and February 1st, respectively, with more shipments scheduled from Lisbon, Coimbra, and Porto through the end of 2023.
